There has been some selling insider activity on Abbott Laboratories Common Stoc (NYSE:ABT) recently. Stephen R. Fussell, EVP disclosed the sale of 196,550 shares. The shares were sold on June 8th for an average price of $46.24. Fussell now owns $8,422,061 of the stock according to the SEC filing. Roger Bird, Sr VP reported the sale of 5,600 shares of (ABT). The shares were purchased at an average price of $43.82. The Sr VP now owns $2,248,536 of the stock per the Form 4 SEC filing.
Joseph J. Manning, Sr VP sold $184,590 worth of shares at an average price of $43.95 on Wed the 26th. The Sr VP now owns $967,955 of the stock as recorded in a recent Form 4 SEC filing.
Abbott Laboratories, launched on March 6, 1900, is involved in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Company, through St. Jude Medical, Inc., also offers a range of products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products..
Here are a few additional firms who have increased or decreased their stake in (ABT). Sowell Financial Services LLC added to its ownership by buying 760 shares an increase of 6.1% from 12/31/2016 to 03/31/2017. Sowell Financial Services LLC controls 13,123 shares worth $571,000. The value of the position overall is up by 5.7%. As of quarter end Piedmont Investment Advisors LLC had bought 360,508 shares growing its position 116.7%. The value of the total investment in Abbott Laboratories Common Stoc went from $11,869,000 to $29,734,000 increasing 150.5% for the reporting period.
Phh Investments, Ltd. divested its position by shedding 372 shares a decrease of 1.1% as of 03/31/2017. Phh Investments, Ltd. owns 34,464 shares valued at $1,531,000. The total value of its holdings increased 7.3%. Ballentine Partners, LLC trimmed its stake by shedding 5,213 shares a decrease of 82.9%. Ballentine Partners, LLC currently owns 1,073 shares with a value of $48,000. The total value of its holdings decreased 80.2%.
On September 13 Jefferies held the company rating at “Buy” and lowered the price expectation from $49.00 to $48.00. July 14 investment analysts at Jefferies made no change to the stock rating of “Buy” but raised the price target to $49.00 from $45.00.
On June 21 the company was changed to a “Buy” in a report from Edward Jones which was a boost from the previous “” rating. June 14 investment analysts at Jefferies left the company rating at “Buy” and moved down the price target to $45.00 from $47.00.
On April 28 the stock rating was downgraded from “” to “Buy” and a price target of $47.00 was set by Piper Jaffray. On March 15 Jefferies held the stock rating at “Buy” but moved up the price target to $47.00 from $45.00.
The company is trading up by 1.22% since yesterday’s close of $46.72. Abbott Laboratories Common Stoc announced a dividend paid on Monday the 15th of May 2017. The dividend payment was $0.265 per share for the quarter which is $1.06 annualized. This dividend represents a yeild of $2.29 which is the dividend as a percentage of the current share price. The ex-dividend date was Tuesday the 11th of April 2017.
The stock is trading at $47.29 marginally over the 50 day moving average of $44.41 and which is marginally over the 200 day moving average of $42.61. The 50 day moving average went up $2.88 or +6.49% and the 200 day average was up $4.68.
The P/E ratio is currently 49.21 and the market value is 82.06B. In the latest earnings report the EPS was $0.96 and is estimated to be $2.47 for the current year with 1,735,272,000 shares outstanding. Analysts expect next quarter’s EPS to be $0.66 and the next full year EPS is anticipated to be $2.76.